Glivec (Imatinib) is a Molecular Therapy for CML & GIST

About Glivec

Target: CML

Target: GIST

Rare Diseases

For Your Patients

News and Events

Resources

European Summary of Product Characteristics

Learn more about Glivec's cutting edge molecularly-targeted treatment mechanism.

Find out how Glivec is transforming the management of certain cancers.

The international patient assistance programme, GIPAP is open in about 80 countries. As of November 30, 2007 the total number of patients reached was 19,378.

Help us improve Glivec.com.
Please take our short survey.



	Positive results prompt US National Cancer Institute to make Glivec available to patients in post-surgical GIST study


	Hassan I, et al. Surgically Managed Gastrointestinal Stromal Tumors: A Comparative and Prognostic Analysis. Annals of Surgical Oncollogy 2008 Jan




	Novartis legal actions in india have generated public interest and inquiry. Find out the novartis perspective and see our demonstrated commitment to providing access to medicines. Visit our Information Center - Glivec India patient case >



	Experience the complete range of communication and branding via a fully interactive virtual exhibit booth, matching the experience of attendees of the 2007 ASH Annual Meeting. American Society of Hematology (ASH) held in Atlanta, Georgia, Dec 2007.



	2008 Gastrointestinal Cancers Symposium American Society of Clinical Oncology (ASCO). January 25-27, 2008 Orlando, Florida.
	National Comprehensive Cancer Network (NCCN). March 5-9, 2008 Hollywood, Florida.




Targeted Therapy in Gastrointestinal Stromal Tumours (GIST) based on data presented at ASCO in 2007.

Our weekly newsletter keeps you informed of the latest haematology and oncology news.

Disclaimer: This is an international website for Glivec (imatinib) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the For US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.